RNAZ – transcode therapeutics, inc. (US:NASDAQ)
Stock Stats
News
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
TransCode Therapeutics Open Letter to Shareholders
TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data
Form 10-Q Transcode Therapeutics, For: Sep 30
Form DEFA14A Transcode Therapeutics,
Form SC 13G/A Transcode Therapeutics, Filed by: 3i, LP
Form DEFA14A Transcode Therapeutics,
Form 8-K Transcode Therapeutics, For: Nov 04
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.